Toutes les photos(1)

Key Documents

COO/COA

View All Documentation

Y0001264

Aciclovir for system suitability

Name: Aciclovir for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Acycloguanosine, 9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₈H₁₁N₅O₃

Numéro CAS:

59277-89-3

Poids moléculaire :

225.20

Numéro MDL:

MFCD00057880

Code UNSPSC :

41116107

ID de substance PubChem :

329831331

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 10

1 of 10

Y0002245

Aciclovir for system suitability A

Y0002242

Aciclovir for impurity C identification

Supelco

PHR1005

Acétaminophène

Millipore

SLHV033N

Filtre pour seringue Millex^® en PVDF

Y0001130

Cimetidine for peak identification

Supelco

PHR1016

Chlorpheniramine Maleate

A0220000

Aciclovir

USP

1479304

Oseltamivir phosphate

Millipore

SLHP033N

Filtre pour seringue Millex^®, polyéthersulfone

Y0002244

Aciclovir for impurity G identification

Qualité

pharmaceutical primary standard

Famille d'API

acyclovir

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES

NC1=Nc2c(ncn2COCCO)C(=O)N1

InChI

1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

Clé InChI

MKUXAQIIEYXACX-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Aciclovir for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

A0220000

Aciclovir, European Pharmacopoeia (EP) Reference Standard

1012065

Acyclovir, United States Pharmacopeia (USP) Reference Standard

1012076

PHR1254

Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001271

Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard

1012087

1012054

Code de la classe de stockage

13 - Non Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients.

Martina Prelog et al.

Pediatric nephrology (Berlin, Germany), 26(5), 663-673 (2010-11-16)

Clear recommendations for the management of acute varicella-zoster virus (VZV) infections for cases of significant exposure and the use of prophylactic drugs after solid-organ transplantation are missing due to the lack of evidence by prospective studies. Heterogeneity in patient groups

A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections.

S Leflore et al.

Drug safety, 23(2), 131-142 (2000-08-17)

The objective of this article is to review and evaluate risks and benefits associated with the use of acyclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was

Aciclovir-resistant herpes keratitis.

Keat Choong et al.

Clinical & experimental ophthalmology, 38(3), 309-313 (2010-05-08)

Herpes simplex virus (HSV) keratitis is a common cause of ocular morbidity. Resistance to aciclovir is probably under recognized. We describe three cases of aciclovir-resistant herpes simplex virus keratitis treated with systemic foscarnet and present a review of the pharmacological

Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.

Todd Hatchette et al.

The Pediatric infectious disease journal, 27(1), 75-77 (2007-12-29)

The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A

Management of acyclovir-resistant herpes simplex virus.

Suneel Chilukuri et al.

Dermatologic clinics, 21(2), 311-320 (2003-05-22)

In immunocompetent patients, HSV is controlled rapidly by the human host's immune system, and recurrent lesions are small and short lived. When treated with antiviral agents, these patients rarely develop resistance to these drugs. In contrast immunocompromised patients might not

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique